<DOC>
	<DOCNO>NCT01842139</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best way give vaccine therapy together basiliximab treat patient acute myeloid leukemia ( AML ) complete remission . Vaccines make WT1 peptide may help body build effective immune response kill cancer cell . Montanide ISA 51 VG poly-ICLC may enhance response . Monoclonal antibody , basiliximab , block cancer growth different way . Some block ability cancer grow spread . Others find cancer cell help kill carry cancer-killing substance . It yet know whether WT1 126-134 peptide vaccine Montanide ISA 51 VG effective poly-ICLC give together basiliximab treat AML</brief_summary>
	<brief_title>Vaccine Therapy Basiliximab Treating Patients With Acute Myeloid Leukemia Complete Remission</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To examine immunogenicity WT1 peptide ( WT1 126-134 peptide vaccine ) emulsify Montanide ( Montanide ISA 51 VG ) elderly patient AML . II . To determine whether toll-like receptor 3 ( TLR3 ) agonist ( poly-L-lysine carboxymethyl cellulose [ poly ICLC ] ) could potent immunologic adjuvant , increase frequency WT1-specific T cell follow vaccination . III . To determine whether depletion regulatory T cell occur upon administration anti-cluster differentiation ( CD ) 25 monoclonal antibody Basiliximab , whether associate increased frequency WT1-specific T cell follow vaccination . IV . To assess whether WT1 vaccination +/- TLR3 agonist ( poly ICLC ) combine Basiliximab result decrease level WT1 transcripts peripheral blood cell compare WT1 vaccination +/- TLR3 measure quantitative reverse transcriptase-polymerase chain reaction ( qRT-PCR ) . SECONDARY OBJECTIVES : I . To examine safety gain preliminary information efficacy WT1 peptide vaccination +/- TLR3 agonist ( poly ICLC ) combine Basiliximab . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive WT1 126-134 peptide vaccine emulsify Montanide ISA 51 VG subcutaneously ( SC ) day 0 every 2 week . ARM B : Patients receive WT1 126-134 peptide vaccine emulsify poly-ICLC SC day 0 every 2 week . ARM C : Patients assign Arm C receive basiliximab intravenously ( IV ) 30 minute day -7 WT1 126-134 peptide vaccine Arm A Arm B , whichever superior cellular immune response . In arm , treatment continue 12 week absence disease progression unacceptable toxicity . Patients may receive 6 additional monthly vaccination . After completion study treatment , patient follow 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Patients Hematological malignancy , include AML , MDS , CML blast phase condition investigator 's discretion . Bone marrow biopsyconfirmed CR CRi , CR1 allow , CR2 CR3 . The enrollee deem candidate stem cell transplant due advance age comorbidities ; enrollee donor available ; enrollee refuse stem cell transplant due personal belief ; stem cell transplant current standard care . Patients post stem cell transplant CR CRi allow immunosuppression , treat systematic steroid GVHD Karnofsky performance status index &gt; = 80 % Written inform consent Absolute neutrophil count &gt; = 500/μl Platelet count &gt; = 20,000/μl transfusion Creatinine = &lt; 2 x upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvate transaminase ( SGPT ) = &lt; 5 x ULN Bilirubin = &lt; 3 x ULN Human leukocyte antigen ( HLA ) typing : patient must express HLAA2 Age &gt; 18 year &lt; 85 year Electrocardiogram ( EKG ) without evidence arrhythmia change indicate acute ischemia Pulse oximetry show oxygen saturation least 90 % room air No irreversible coagulopathy , international normalize ratio ( INR ) = &lt; 2 No sign tumor lysis syndrome , uric acid need normal range prior treatment Not diabetic ketoacidosis ( DKA ) , sickle cell crisis , severe peripheral vascular disease active anticoagulation treatment Pregnant nursing woman ; woman still childbearing potential must test urinary serum beta human chorionic gonadotropin ( βHCG ) Biological chemotherapy 4 week prior start dose Patients intrinsic immunosuppression , include seropositivity human immunodeficiency virus ( HIV ) antibody ; patient test HIV Serious concurrent infection , include active tuberculosis , hepatitis B , hepatitis C ; patient test hepatitis B surface antigen hepatitis C antibody ; patient hepatitis C antibody ( Ab ) positive eligible PCR negative Active history confirm autoimmune disease Concurrent systemic corticosteroid ( except physiologic replacement dos ) immunosuppressive drug ( eg . cyclosporin A ) Active history autoimmune disease include limited rheumatoid arthritis ( rheumatoid factor [ RF ] positive current recent flare ) , inflammatory bowel disease , systemic lupus erythematosus ( clinical evidence antinuclear antibody [ ANA ] 1:80 great ) , ankylose spondylitis , scleroderma , multiple sclerosis , autoimmune hemolytic anemia , immune thrombocytopenic purpura ; seropositivity alone consider positive Psychiatric illness may make compliance clinical protocol unmanageable may compromise ability patient give informed consent ; patient clinical evidence dementia competent designee participate decision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>